Literature DB >> 6405474

Recent advances in management of bacterial diarrhea.

R Fekety.   

Abstract

The number of recognized infectious causes of diarrhea potentially treatable with specific antibiotics has markedly increased within the past ten years. Laboratories are developing and expanding their abilities to deal with these new pathogens. Neither prophylaxis nor specific treatment of diarrhea in travelers is simple, practical, and safe. Although enterotoxigenic Escherichia coli is the most important cause of diarrhea in U.S. travelers to tropical areas, Campylobacter jejuni causes acute diarrhea in persons in the United States about as often as do Salmonella and Shigella. Vibrio parahemolyticus is an important cause of outbreaks of gastroenteritis following ingestion of improperly cooked shellfish; Bacillus cereus is important in outbreaks of diarrhea after ingestion of improperly cooked and stored rice in Chinese restaurants. Although Yersinia enterocolitica is probably an important cause of severe enteritis in the United States, imperfect techniques for its isolation and lack of good serologic tests have hampered recognition of its importance. Practical means for diagnosing antibiotic-associated colitis and the role of Clostridium difficile toxins in this disease are now available. Vancomycin, metronidazole, bacitracin, and cholestyramine are useful in treatment of antibiotic-associated colitis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6405474     DOI: 10.1093/clinids/5.2.246

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  6 in total

1.  The evaluation and management of acute diarrhea.

Authors:  S W Tolle; D L Elliot
Journal:  West J Med       Date:  1984-02

Review 2.  The clinical significance of antibiotic-associated pseudomembranous colitis in the 1990s.

Authors:  M Andréjak; J L Schmit; A Tondriaux
Journal:  Drug Saf       Date:  1991 Sep-Oct       Impact factor: 5.606

3.  Nosocomial diarrhoeas in a surgical division hyperendemic for Clostridium difficile: epidemiologic aspects emerging from an analysis of clinical records.

Authors:  P Urbano; S Le Brun
Journal:  Eur J Epidemiol       Date:  1986-12       Impact factor: 8.082

4.  Studies with temocillin in the hamster model of antibiotic-associated colitis.

Authors:  R J Boon; A S Beale
Journal:  Drugs       Date:  1985       Impact factor: 9.546

5.  Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea.

Authors:  F de Lalla; R Nicolin; E Rinaldi; P Scarpellini; R Rigoli; V Manfrin; A Tramarin
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

6.  Treatment of Clostridium difficile-associated disease with teicoplanin.

Authors:  F de Lalla; G Privitera; E Rinaldi; G Ortisi; D Santoro; G Rizzardini
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.